Tasha Thomas is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on proceedings before the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office under the America Invents Act and appeals before the U.S. Court of Appeals for the Federal Circuit. She has experience in matters covering a wide range of technologies, including mechanical devices, optical systems, medical devices, and pharmaceuticals. She is involved in all stages of AIA post-grant proceedings, from pre-institution briefing, trial before the Board, to subsequent appeals before the Federal Circuit.
Tasha Thomas is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on proceedings before the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office under the America Invents Act and appeals before the U.S. Court of Appeals for the Federal Circuit. She has experience in matters covering a wide range of technologies, including mechanical devices, optical systems, medical devices, and pharmaceuticals. She is involved in all stages of AIA post-grant proceedings, from pre-institution briefing, trial before the Board, to subsequent appeals before the Federal Circuit.
- J.D., The George Washington University Law School, 2014
- B.S., Mechanical Engineering, Massachusetts Institute of Technology, 2009
- Bar of the District of Columbia
- State Bar of Maryland
- U.S. Court of Appeals for the Federal Circuit
- U.S. Court of Appeals for the Ninth Circuit
- U.S. Patent and Trademark Office
- J.D., The George Washington University Law School, 2014
- B.S., Mechanical Engineering, Massachusetts Institute of Technology, 2009
- Bar of the District of Columbia
- State Bar of Maryland
- U.S. Court of Appeals for the Federal Circuit
- U.S. Court of Appeals for the Ninth Circuit
- U.S. Patent and Trademark Office
Select Matters
-
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland GmbH, IPR2018-01670, IPR2018-01675, IPR2018-01676, IPR2018-01678, IPR2018-01679, IPR2018-01680, IPR2018-01682, IPR2019-00122 (P.T.A.B.)
- Represented Mylan Pharmaceuticals, Inc., as Petitioner, securing favorable final written decisions finding challenged claims relating to a pen-type injector for drug delivery unpatentable
- Represented Mylan as appellee in securing affirmances in appeals before the Federal Circuit
-
Align Tech., Inc. v. 3Shape A/S, IPR2020-01087 (P.T.A.B.)
- Represented Align Technologies, Inc., as Petitioner, securing a final written decision finding all challenged claims relating to an optical three-dimensional surface scanning system unpatentable
-
Palette Life Sciences, Inc. v. Incept LLC, IPR2020-00002, IPR2020-00004 (P.T.A.B.)
- Represented Palette Life Sciences, Inc., as Petitioner, securing final written decisions finding all challenged claims relating to injectable filler materials for radiation therapy unpatentable
- Currently representing Palette as appellee in appeals before the Federal Circuit
-
Pain Point Med. Sys., inc. v. Blephex, LLC, IPR2016-01670 (P.T.A.B.)
- Represented Blephex, LLC, as Patent Owner, securing a final written decision finding all challenged claims relating to an eyelid abrasion device not unpatentable
Select Matters
-
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland GmbH, IPR2018-01670, IPR2018-01675, IPR2018-01676, IPR2018-01678, IPR2018-01679, IPR2018-01680, IPR2018-01682, IPR2019-00122 (P.T.A.B.)
- Represented Mylan Pharmaceuticals, Inc., as Petitioner, securing favorable final written decisions finding challenged claims relating to a pen-type injector for drug delivery unpatentable
- Represented Mylan as appellee in securing affirmances in appeals before the Federal Circuit
-
Align Tech., Inc. v. 3Shape A/S, IPR2020-01087 (P.T.A.B.)
- Represented Align Technologies, Inc., as Petitioner, securing a final written decision finding all challenged claims relating to an optical three-dimensional surface scanning system unpatentable
-
Palette Life Sciences, Inc. v. Incept LLC, IPR2020-00002, IPR2020-00004 (P.T.A.B.)
- Represented Palette Life Sciences, Inc., as Petitioner, securing final written decisions finding all challenged claims relating to injectable filler materials for radiation therapy unpatentable
- Currently representing Palette as appellee in appeals before the Federal Circuit
-
Pain Point Med. Sys., inc. v. Blephex, LLC, IPR2016-01670 (P.T.A.B.)
- Represented Blephex, LLC, as Patent Owner, securing a final written decision finding all challenged claims relating to an eyelid abrasion device not unpatentable
Wilson Sonsini partner T.O. Kong argued the case at the PTAB and the Federal Circuit, with support from Tasha Thomas, Lori Westin, Rick Torczon, Kathryn Robinson, and Robyn Moriarty.
This latest success follows previous wins against Sanofi's insulin glargine formulation patents. Insulin glargine is used to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. In November, Viatris launched branded and unbranded versions of insulin glargine, the first-ever interchangeable biosimilar.
Wilson Sonsini represents Mylan in patent matters, including those related to this litigation. The team representing Mylan in these appeals includes Rick Torczon, Ellie Steiner, Tasha Thomas, Wes Derryberry, and Steffen Johnson.
- Privacy Policy
- Terms of Use
- Accessibility